When targeting genes, drug developers may opt for knockdown via CRISPR or silencing via RNAi. These weapons, however, may fit different battle plans.
A string of acquisitions has revenue rolling at Charles River Laboratories, and the CRO has inked another M&A deal it hopes will pay off with a larger market share.
In this interview, James Foster, chairman and CEO at Charles River Laboratories spoke about the Company's Q3 earnings, the acquisition of ChanTest and why the work we do is so important.
Institutions that work with lab animals should establish a “culture of care” to make sure animals are treated with compassion. Animal welfare isn’t just good for the animal; it also affects the quality of science and the lives of the people and animals that stand to benefit from the research.
GEN recently interviewed seven experts to learn just what makes a good mouse model for biopharmaceutical research and to find out for which applications and diseases better models are most needed.
Joseph Cornicelli, a Scientific Advisor of Charles River Discovery Services in the areas of inflammation and metabolic and cardiovascular diseases, weighs in on recent data that appear to dampen the health risks of obesity.
Although it is too early to say if cellular models have an effect on drug attrition, more assays have been added to the testing cascade to help mitigate risk. Emphasis is placed on demonstrating target engagement and modulation. Program dependent, new assays are developed and integrated into the cascade.
50 years ago this year, scientists first connected an ancient sea creature (horseshoe crab), to testing for life-threatening bacteria.
John Dubczak, general manager of Charles River Laboratories’ Endotoxin and Microbial Detection division, recently shared trends in the rapid microbiological testing market, and the history of LAL-based systems in this article from Contract Pharma.
Nearly 50 years ago, scientists discovered the horseshoe crab's clotting response to bacterial toxins. Now, its blood is harvested in huge quantities to be used in a test to ensure medical products are not contaminated.
Mad Money host Jim Cramer speaks with James Foster about the Company’s Q2 earnings and why the work we do is so important.